MedPath

Tapinarof

Generic Name
Tapinarof
Brand Names
Vtama
Drug Type
Small Molecule
Chemical Formula
C17H18O2
CAS Number
79338-84-4
Unique Ingredient Identifier
84HW7D0V04
Background

Tapinarof is a novel, first-in-class, small-molecule AhR agonist that is indicated for the treatment of adult psoriasis. It is available as a topical cream to be applied to the affected area once daily. Tapiranof was first discovered as a metabolite (3,5-dihydroxy-4-isopropylstilbene) produced in Photorhabdus luminescens, a gram-negative bacillus that lives symbiotically with the Heterorhabditis nematodes. In 1959, it was noticed that Heterorhabditis with a high amount of 3,5-dihydroxy-4-isopropylstilbene did not putrefy once dead, thus suggesting its potential anti-inflammatory activity.

Tapinarof received initial approval from the FDA in 2022.

Indication

Tapinarof is indicated for the topical treatment of plaque psoriasis in adults.

Associated Conditions
Psoriasis Vulgaris (Plaque Psoriasis)
Clinical Trials
Related News

Aprocitentan Shows Promising Results in Black Adults with Resistant Hypertension

• Aprocitentan, a novel dual endothelin receptor antagonist, demonstrated significant blood pressure reduction in Black adults with resistant hypertension in recent clinical trials. • The treatment showed efficacy in a population that traditionally experiences higher rates of treatment-resistant hypertension and disproportionate cardiovascular outcomes. • Researchers highlight aprocitentan's potential to address an important unmet need in hypertension management, particularly for demographic groups with limited therapeutic options.

Conduit Pharmaceuticals Files Novel Cocrystal Patent for VTAMA, Extending Therapeutic Potential Beyond 2027

• Conduit Pharmaceuticals has filed groundbreaking patents for a dual active cocrystal formulation of tapinarof (VTAMA®), potentially addressing both inflammatory conditions and associated symptoms like pain and itch. • The strategic patent filing comes as VTAMA approaches its 2027 exclusivity expiration, positioning Conduit for high-value licensing partnerships in the $233.6 billion anti-inflammatory therapeutics market. • The novel cocrystal approach aims to improve patient tolerability, extend patent protection, and expand therapeutic applications beyond psoriasis and atopic dermatitis into other inflammatory and autoimmune conditions.

CDMO Market Report: Key Regulatory Approvals and Clinical Advances in March-April 2025

• Multiple CDMOs secured significant contract manufacturing opportunities as regulatory bodies approved new indications for established drugs, particularly in oncology and rare diseases. • AstraZeneca's portfolio saw substantial growth with expanded approvals for Imfinzi, Tagrisso, and Lynparza, strengthening partnerships with contract manufacturers including Lonza, Dottikon, and Samsung Biologics. • Contract manufacturers supporting treatments for autoimmune conditions showed strong performance, with Argenx's Vyvgart Hytrulo receiving expanded indications for myasthenia gravis and CIDP.

Dupilumab Shows Promise in Reducing IgE Levels in Food Allergy Patients

• A recent small-scale study demonstrates that dupilumab treatment significantly reduces IgE levels in patients with food allergies, suggesting potential therapeutic benefits beyond its approved indications. • Researchers observed that participants with food allergies treated with dupilumab showed measurable decreases in allergen-specific IgE, potentially reducing sensitivity to food triggers. • The findings align with dupilumab's established efficacy in related conditions, including asthma, chronic rhinosinusitis with nasal polyps, and atopic dermatitis, expanding its potential therapeutic applications.

FDA Approves Organon's Vtama (Tapinarof) Cream for Atopic Dermatitis in Adults and Children

• The FDA has approved Vtama (tapinarof) cream 1% for treating atopic dermatitis in adults and children aged 2 years and older. • Vtama demonstrated statistically significant improvements in skin clearance and itch reduction compared to the vehicle in clinical trials. • The treatment offers a steroid-free option with no label warnings, contraindications, or restrictions on treatment duration or body surface area affected. • Long-term studies showed sustained efficacy and a favorable safety profile, with many patients experiencing extended treatment-free intervals.

Galderma's Nemolizumab (Nemluvio) Receives FDA Approval for Moderate-to-Severe Atopic Dermatitis

• The FDA has approved Nemluvio (nemolizumab) for moderate-to-severe atopic dermatitis in patients 12 years and older when topical treatments are inadequate. • Nemolizumab is the first monoclonal antibody targeting IL-31 receptor alpha, offering a novel approach to reduce itch and inflammation associated with atopic dermatitis. • Clinical trials showed significant improvements in skin clearance, itch relief, and sleep disturbance with nemolizumab in combination with topical treatments. • Galderma anticipates peak sales of nemolizumab to exceed $2 billion, with potential blockbuster status by the end of 2027.

FDA Wraps Up 2024 with Key Approvals for Drugs Targeting Various Conditions

• The FDA approved Vertex's Alyftrek for cystic fibrosis, offering improved dosing and potential market exclusivity. • Novo Nordisk's Alhemo was approved for hemophilia A and B, providing a new option for patients with inhibitors. • Bristol Myers Squibb's Opdivo Qvantig gained approval as a subcutaneous formulation, offering faster administration for various solid tumors. • Eli Lilly's Zepbound secured approval for obstructive sleep apnea in obese adults, marking the first prescription medicine for this condition.

J&J's Oral IL-23 Inhibitor Icotrokinra Achieves Positive Phase 3 Results in Psoriasis

• Johnson & Johnson's icotrokinra met primary endpoints in the ICONIC-LEAD phase 3 trial, demonstrating significant skin clearance in psoriasis patients. • After 16 weeks, 64.7% of patients achieved clear or almost clear skin (IGA 0/1), and 49.6% showed a 90% or greater improvement in PASI score. • Icotrokinra's tolerability profile was consistent with previous phase 2 studies, with similar adverse event rates compared to placebo. • J&J plans to submit icotrokinra for regulatory approval, positioning it as a potential oral alternative to injectable biologics for psoriasis.

FDA Weighs Removal of Oral Phenylephrine; Approves Drugs for CML, Gastric Cancer, and UTIs

• The FDA is considering removing oral phenylephrine from its OTC Monograph due to a lack of efficacy as a nasal decongestant, potentially impacting numerous cold and allergy products. • Novartis' Scemblix expands its FDA-approved uses to include the treatment of newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ PML). • Astellas Pharma's Vyloy (zolbetuximab) receives FDA approval as the first treatment targeting the CLDN18.2 protein for gastric or gastroesophageal junction adenocarcinoma. • Iterum Therapeutics' Orlynvah (sulopenem) gains FDA approval for treating uncomplicated urinary tract infections in women with limited oral antibacterial treatment options.

FDA Extends Review of Organon's Vtama for Atopic Dermatitis to March

• The FDA has extended the review period for Organon's Vtama cream for treating atopic dermatitis, setting a new target action date for March 12. • The extension was prompted by the FDA's request for final datasets and the clinical-study report from a long-term extension study. • Organon anticipates Vtama will contribute approximately $125 million in revenue next year due to the delay, impacting 2025 earnings. • The FDA has not raised concerns about the safety or efficacy of Vtama, which is already approved for plaque psoriasis treatment.

Vtama Cream Shows Positive Long-Term Results in Atopic Dermatitis Trial

• Dermavant's Vtama (tapinarof) cream demonstrated efficacy and safety in treating atopic dermatitis (AD) in patients as young as two years old. • In a long-term extension study, 51.9% of patients achieved complete disease clearance at least once during the 48-week study period. • Patients who achieved complete disease clearance experienced an average treatment-free interval of nearly 80 days after discontinuing Vtama. • The FDA is expected to make a decision on Dermavant’s application for Vtama in AD in the fourth quarter of this year.

Dermatology Advances: Approvals, Trial Results, and New Guidelines Emerge

• The FDA approved bimekizumab for moderate-to-severe hidradenitis suppurativa, marking the first treatment targeting both IL-17A and IL-17F cytokines. • Subcutaneous nivolumab's PDUFA date was updated, based on Phase 3 data demonstrating noninferiority to intravenous nivolumab in renal cell carcinoma. • New clinical guidelines emphasize image-guided superficial radiation therapy for nonmelanoma skin cancers, improving precision in treating basal and squamous cell carcinoma. • Phase 2b trial results show mRNA-4157 combined with pembrolizumab significantly improves recurrence-free survival in high-risk stage III/IV melanoma patients.

New Topical Treatments Expand Options for Dermatological Conditions: Expert Highlights Ruxolitinib and Roflumilast Advances

• Topical ruxolitinib (Opzelura) demonstrates strong long-term efficacy for atopic dermatitis in patients as young as 2 years old, with FDA approval currently for ages 12+ and vitiligo treatment. • Roflumilast cream 0.15% (Zoryve) receives approval for atopic dermatitis in patients aged 6 and older, while the 0.3% foam formulation is approved for seborrheic dermatitis in patients aged 9+. • Both medications show excellent safety and tolerability profiles, with roflumilast's lower strength formulation specifically designed to address concerns about systemic absorption in younger patients.

Organon Expands Dermatology Portfolio with $1.2 Billion Acquisition of Dermavant

• Organon is set to acquire Dermavant for up to $1.2 billion, gaining Vtama (tapinarof) cream, a commercialized plaque psoriasis drug. • Vtama, a non-steroidal topical cream, is under FDA review for atopic dermatitis, with a decision expected in Q4, potentially triggering a $75 million milestone payment. • Organon aims to leverage its global reach to maximize Vtama's commercial potential, combining Dermavant's U.S. presence with Organon's market access and regulatory expertise. • Roivant's sale of Dermavant aligns with its strategy to focus on specialty drug candidates with blockbuster potential, following previous sales and new subsidiary launches.

Dermatology Experts Highlight Advances in Treatment and Clinical Trial Diversity

• Experts at the Skin of Color Update 2024 emphasized the importance of diversity in clinical trials to address health disparities and improve data for all patient populations. • Recent FDA approvals of topical therapies like roflumilast and tapinarof for atopic dermatitis and other conditions were highlighted for their efficacy and safety. • Advances in biologic therapies, including bimekizumab, secukinumab, and nemolizumab, offer new treatment options for conditions like psoriasis, hidradenitis suppurativa and prurigo nodularis. • The FDA's Diversity Action Plan (DAP) aims to increase the enrollment of underrepresented groups in clinical trials, ensuring treatments are effective across diverse populations.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy